Australian Doctor Australian Doctor 24th November 2017 | Page 5

Primary lost for words in legal fight

ANTONY SCHOLEFIELD IT’ S taken seven years, a team of high-cost lawyers and numerous court dates but the verdict is in: Primary Health Care cannot legally trademark the words‘ Primary Health Care’.
The GP corporate wanted to protect its name amid fears that doctors and the public may confuse it with other organisations that use the words in their branding.
In 2010, it prosecuted the Australian General Practice Network, whose members had been branding themselves as primary health care organisations.
Four years later, the Federal Government— in the process of setting up its primary health networks— blocked Primary from registering the trademark.
Now, after a prolonged legal battle, the Federal
Court has ruled against Primary, noting that the phrase‘ primary health care’ has been around a long time.
The court’ s 50,000-word judgement makes clear that this historical fact was lost on Henry Bateman, Primary’ s one-time general manager, who apparently did not realise the phrase related to anything other than the company founded by his father, Dr Ed Bateman.
The younger Bateman told the court he used Collins, Macquarie and Oxford dictionaries to look up‘ primary health care’, but found nothing there. His research left Federal Court judge Anna Katzmann unimpressed, however.
“ The term‘ health check’ does not appear in the dictionary,” she wrote in her judgement.“ Nor, for that matter, does‘ ham sandwich
’. Each term, however, has an ordinary meaning.
“ Despite the professed ignorance of his son, the evidence indicated that the name was chosen by the applicant’ s founder, Dr Edmund Bateman, because it reflected the services that would be available to patients attending the centres,” she added.
Mr Bateman left the company in 2016.
Mr Bateman tried to trademark‘ primary health care’.

In Brief

Staff writers

COMPREHENSIVE MENINGOCOCCAL COVERAGE * NOW AVAILABLE FOR YOUR TINIEST PATIENTS 1 – 3

Fall in‘ unacceptable’ GP waiting times
FEWER Australians are facing unacceptable wait times for a GP appointment than three years ago. More than 83 % of respondents to the latest ABS Patient Experiences in Australia survey reported seeing a GP in the 12 months to June 2017. Just 18 % said they faced unacceptable delays to see a GP in that time, compared with 23 % in 2013-14.
New president for rural doctors’ lobby
THE RDAA has elected a new president after nearly a month of searching. Queensland GP Dr Adam Coltzau is promising to“ fight for the rights of rural people” after being named president last week. Dr Coltzau takes over from fellow Queenslander Dr Ewen McPhee.
*
Menveo + Bexsero helps protect against the most common disease-causing serogroups in Australia 1-3
Menveo is now the first and only meningococcal ACW 135 Y conjugate vaccine approved for use in babies from 2 months of age 1
Meningococcal B is currently † the dominant disease-causing serogroup among babies under 12 months, but other serogroups such as W and Y pose an emerging threat. 4
B A C W Y
Multicomponent Meningococcal group B vaccine( recombinant, adsorbed)
Colours not representative of serogroup prevalence. † Current as of 18 October 2017.
Euthanasia bill fails A BILL to allow patients 25 years or older, whose deaths are imminent and who are in excruciating pain to choose euthanasia, was voted down by one vote last week in the NSW Parliament. MPs teared up as they made their pleas for and against the bill during a lengthy debate in the Legislative Council, which ran late into the night.
Please review Product Information before prescribing. See primary advertisement in this publication for Minimum Product Information. Full Product Information for each product is available at au. gsk. com
PBS Information: These products are not listed on the National Immunisation Program( NIP) or the PBS.
References: 1. Menveo Approved Product Information. 2. Bexsero Approved Product Information. 3. Australian Government Department of Health. Australian Immunisation Handbook 10th Edition. www. immunise. health. gov. au / internet / immunise / publishing. nsf / content / Handbook10-home ~ handbook10part4 ~ handbook10-4-10. Accessed September 2017. 4. Invasive Meningococcal W Disease National Surveillance Reports. www. health. gov. au / internet / main / publishing. nsf / Content / ohp-meningococcal-W. htm. Accessed September 2017.
For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109. GlaxoSmithKline Australia Pty Ltd. ABN 47 100 162 481. Melbourne, VIC. Trade marks are owned or licensed to the GSK group of companies. © 2017 GSK group of companies or its licensor. AUS / MNV / 0022 / 17. Date of Approval October 2017. MEN0146 / AD.
www. australiandoctor. com. au 24 November 2017 | Australian Doctor | 5